Evans H, Baumgartner M, Shine J, Herzog H (decembro de 1993). "Genomic organization and localization of the gene encoding human preprogalanin". Genomics18 (3): 473–7. PMID7508413. doi:10.1016/S0888-7543(11)80002-9.
Lundström L, Elmquist A, Bartfai T, Langel U (2005). "Galanin and its receptors in neurological disorders". Neuromolecular Med.7 (1–2): 157–80. PMID16052044. doi:10.1385/NMM:7:1-2:157.
Berger A, Santic R, Hauser-Kronberger C, Schilling FH, Kogner P, Ratschek M, Gamper A, Jones N, Sperl W, Kofler B (xuño de 2005). "Galanin and galanin receptors in human cancers". Neuropeptides39 (3): 353–9. PMID15944034. doi:10.1016/j.npep.2004.12.016.
Wynick D, Thompson SW, McMahon SB (febreiro de 2001). "The role of galanin as a multi-functional neuropeptide in the nervous system". Current Opinion in Pharmacology1 (1): 73–7. PMID11712539. doi:10.1016/S1471-4892(01)00006-6.
Hökfelt T, Tatemoto K (xuño de 2008). "Galanin--25 years with a multitalented neuropeptide". Cell. Mol. Life Sci.65 (12): 1793–5. PMID18500648. doi:10.1007/s00018-008-8152-9.
Kuteeva E, Hökfelt T, Wardi T, Ogren SO (2010). Hökfelt T, ed. "Galanin, galanin receptor subtypes and depression-like behaviour". Experientia Supplementum (Basel: Springer) 102: 163–81. ISBN978-3-0346-0227-3. PMID21299068. doi:10.1007/978-3-0346-0228-0_12.
Ch'ng JL, Christofides ND, Anand P, Gibson SJ, Allen YS, Su HC, et al. (outubro de 1985). "Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury". Neuroscience16 (2): 343–54. PMID2417156. doi:10.1016/0306-4522(85)90007-7.
Bersani M, Johnsen AH, Højrup P, Dunning BE, Andreasen JJ, Holst JJ (xuño de 1991). "Human galanin: primary structure and identification of two molecular forms". FEBS Lett.283 (2): 189–94. PMID1710578. doi:10.1016/0014-5793(91)80585-Q.
Lang R, Gundlach AL, Kofler B (agosto de 2007). "The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease". Pharmacol. Ther.115 (2): 177–207. PMID17604107. doi:10.1016/j.pharmthera.2007.05.009.
Fang P, Yu M, Shi M, Bo P, Zhang Z (xaneiro de 2020). "Galanin peptide family regulation of glucose metabolism". Frontiers in Neuroendocrinology56: 100801. PMID31705911. doi:10.1016/j.yfrne.2019.100801.
Genders SG, Scheller KJ, Djouma E (marzo de 2020). "Neuropeptide modulation of addiction: Focus on galanin". Neuroscience and Biobehavioral Reviews110: 133–149. PMID29949733. doi:10.1016/j.neubiorev.2018.06.021.
Counts SE, Perez SE, Ginsberg SD, De Lacalle S, Mufson EJ (maio de 2003). "Galanin in Alzheimer disease". Mol. Interv.3 (3): 137–56. PMID14993421. doi:10.1124/mi.3.3.137.
Ding X, MacTavish D, Kar S, Jhamandas JH (febreiro de 2006). "Galanin attenuates beta-amyloid (Abeta) toxicity in rat cholinergic basal forebrain neurons". Neurobiol. Dis.21 (2): 413–20. PMID16246567. doi:10.1016/j.nbd.2005.08.016.
Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS (Dec 2008). "Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities". Journal of Medicinal Chemistry51 (24): 8038–47. PMID19053761. doi:10.1021/jm801088x.
Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, Pope R, et al. (2010). Hökfelt T, ed. "Galanin acts as a trophic factor to the central and peripheral nervous systems". Experientia Supplementum (Basel: Springer) 102: 25–38. ISBN978-3-0346-0227-3. PMID21299059. doi:10.1007/978-3-0346-0228-0_3.
Evans H, Baumgartner M, Shine J, Herzog H (decembro de 1993). "Genomic organization and localization of the gene encoding human preprogalanin". Genomics18 (3): 473–7. PMID7508413. doi:10.1016/S0888-7543(11)80002-9.
Lundström L, Elmquist A, Bartfai T, Langel U (2005). "Galanin and its receptors in neurological disorders". Neuromolecular Med.7 (1–2): 157–80. PMID16052044. doi:10.1385/NMM:7:1-2:157.
Berger A, Santic R, Hauser-Kronberger C, Schilling FH, Kogner P, Ratschek M, Gamper A, Jones N, Sperl W, Kofler B (xuño de 2005). "Galanin and galanin receptors in human cancers". Neuropeptides39 (3): 353–9. PMID15944034. doi:10.1016/j.npep.2004.12.016.
Wynick D, Thompson SW, McMahon SB (febreiro de 2001). "The role of galanin as a multi-functional neuropeptide in the nervous system". Current Opinion in Pharmacology1 (1): 73–7. PMID11712539. doi:10.1016/S1471-4892(01)00006-6.
Hökfelt T, Tatemoto K (xuño de 2008). "Galanin--25 years with a multitalented neuropeptide". Cell. Mol. Life Sci.65 (12): 1793–5. PMID18500648. doi:10.1007/s00018-008-8152-9.
Kuteeva E, Hökfelt T, Wardi T, Ogren SO (2010). Hökfelt T, ed. "Galanin, galanin receptor subtypes and depression-like behaviour". Experientia Supplementum (Basel: Springer) 102: 163–81. ISBN978-3-0346-0227-3. PMID21299068. doi:10.1007/978-3-0346-0228-0_12.
Ch'ng JL, Christofides ND, Anand P, Gibson SJ, Allen YS, Su HC, et al. (outubro de 1985). "Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury". Neuroscience16 (2): 343–54. PMID2417156. doi:10.1016/0306-4522(85)90007-7.
Bersani M, Johnsen AH, Højrup P, Dunning BE, Andreasen JJ, Holst JJ (xuño de 1991). "Human galanin: primary structure and identification of two molecular forms". FEBS Lett.283 (2): 189–94. PMID1710578. doi:10.1016/0014-5793(91)80585-Q.
Lang R, Gundlach AL, Kofler B (agosto de 2007). "The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease". Pharmacol. Ther.115 (2): 177–207. PMID17604107. doi:10.1016/j.pharmthera.2007.05.009.
Fang P, Yu M, Shi M, Bo P, Zhang Z (xaneiro de 2020). "Galanin peptide family regulation of glucose metabolism". Frontiers in Neuroendocrinology56: 100801. PMID31705911. doi:10.1016/j.yfrne.2019.100801.
Genders SG, Scheller KJ, Djouma E (marzo de 2020). "Neuropeptide modulation of addiction: Focus on galanin". Neuroscience and Biobehavioral Reviews110: 133–149. PMID29949733. doi:10.1016/j.neubiorev.2018.06.021.
Counts SE, Perez SE, Ginsberg SD, De Lacalle S, Mufson EJ (maio de 2003). "Galanin in Alzheimer disease". Mol. Interv.3 (3): 137–56. PMID14993421. doi:10.1124/mi.3.3.137.
Ding X, MacTavish D, Kar S, Jhamandas JH (febreiro de 2006). "Galanin attenuates beta-amyloid (Abeta) toxicity in rat cholinergic basal forebrain neurons". Neurobiol. Dis.21 (2): 413–20. PMID16246567. doi:10.1016/j.nbd.2005.08.016.
Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS (Dec 2008). "Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities". Journal of Medicinal Chemistry51 (24): 8038–47. PMID19053761. doi:10.1021/jm801088x.
Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, Pope R, et al. (2010). Hökfelt T, ed. "Galanin acts as a trophic factor to the central and peripheral nervous systems". Experientia Supplementum (Basel: Springer) 102: 25–38. ISBN978-3-0346-0227-3. PMID21299059. doi:10.1007/978-3-0346-0228-0_3.